Latest Covid-19 updates

Brand Name

J&J claims that its vaccine provides at least 8 months of immunity against the Delta Variant.

Latest news of Covid-19

Friday, 2nd July 2021

Johnson & Johnson claims that its single-shot coronavirus vaccine neutralises the fast-spreading delta form while also providing long-term protection from illness.

The business stated in a statement on Thursday that vaccine recipients produced strong neutralising antibodies against all forms of the virus for at least eight months, including delta, which was originally seen in India and has since spread around the world.

According to the Centers for Disease Control and Prevention, Delta is projected to become the prevalent strain in the United States in the coming weeks. The J&J shot offers less immediate protection than messenger RNA vaccines from Pfizer Inc. and Moderna Inc., and researchers are debating whether some people will require booster shots to keep the virus at bay in the long run.

In an interview, Johan Van Hoof, J&J's worldwide head of infectious diseases and vaccinations, said, "We're actually extremely satisfied and certain there's no need for the booster at the moment and we're protected against different strains."

According to the business, the injection neutralised the delta variation within 29 days of the first dose, and protection evolved and increased over time.

With the most recent statistics, Van Hoof stated that J&J believes that those who have received the vaccination should not require a booster within a year of receiving it. "And we don't anticipate we'll need to adjust the formulation if we need a boost," he added.

Scientists and certain vaccine makers have been working on new versions of their vaccines to directly target the developing strains, which have proven to be far more transmissible than the original virus that first appeared in Wuhan, China, in late 2019.

The pathogen's ongoing evolution, on the other hand, makes it an ever-moving target, prompting some to wonder if extra doses of existing vaccines could provide more protection.

J&J revealed the results of two tests on Thursday.

The business tested the neutralising antibodies produced against the delta version in the blood samples of eight participants in a late-stage clinical trial of the vaccine. Dan Barouch of Beth Israel Deaconess Medical Center assessed the immune response's endurance in 20 early-stage vaccine research participants.

According to the company, more robust data will be published on bioRxiv, an online research repository.

Regimen of Two Shots

Antibody counts, known as titres, were significantly greater in reaction to the delta variation than the beta variant first discovered in South Africa, according to data supplied by the business.

A second dosage of J&J's vaccine has been shown to boost a person's antibody count. Van Hoof said the company intends to release efficacy data from a late-stage trial of a two-shot regimen at the end of August.

The company is also looking into the vaccine's ability to generate T cells, which is another indicator of its effectiveness. According to Van Hoof, the shot increased T cell immunity against the virus and its variations over the course of eight months.

J&J's injection has struggled to gain traction due to production issues and a brief halt in use as regulators investigated claims that some people received it and developed deadly blood clots. On April 23, the halt was lifted after ten days.


The News Talkie Bureau



Top Stories
Download video from a Converthub online ..
Impact Feature: अमेरिकन ..
South Newsmakers of Week: Ram Charan & S..
What Makes Gandhis CWC a Team Amidst the..
Kerala Sees a Dip in Total Covid-19 Case..
Bangladesh “Just not Good Enough”, S..
Udanpirappe Movie Review: A family drama..
5 Superfood-Enriched Products for Health..
5 Superfoods Against Anxiety and Stress..
5 Small Lifestyle Changes You Can Make t..